These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20832548)

  • 1. Sirolimus in liver transplant recipients: a large single-center experience.
    Vivarelli M; Dazzi A; Cucchetti A; Gasbarrini A; Zanello M; Di Gioia P; Bianchi G; Tamè MR; Gaudio MD; Ravaioli M; Cescon M; Grazi GL; Pinna AD
    Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
    Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
    Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
    Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
    Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
    Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
    Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
    Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
    Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indications and management of everolimus after liver transplantation.
    Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
    Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial.
    Shenoy S; Hardinger KL; Crippin J; Desai N; Korenblat K; Lisker-Melman M; Lowell JA; Chapman W
    Transplantation; 2007 May; 83(10):1389-92. PubMed ID: 17519792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
    Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
    Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
    Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
    Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.